Axio BioPharma

Today is Employee Appreciation Day, and at Axio BioPharma we want to recognize the team behind our mission to accelerate biologics from concept to clinic.
Every day, our scientists, engineers, and operators are working to solve one of the biggest challenges in drug development: ensuring critical process data flows seamlessly across sites and partners.

From our high-throughput antibody lab to the coordination layer we are building across the biologics ecosystem, none of this progress happens without the expertise, dedication, and collaboration of our people.

Thank you to the team that is helping fix the data handoffs that slow drug development and bringing the industry one step closer to faster, more efficient biologics development.

"Behind every breakthrough at Axio BioPharma are people who care deeply about why the work matters.

One of those people is Tristan McAloon, our Director of Commercial Operations, who plays a key role in advancing the high-throughput processes that help us move faster and smarter. From streamlining operations to continuously elevating the customer experience, Tristan helps ensure innovation reaches those who need it without delay.

For Tristan, this mission is personal. Growing up, he watched his father battle autoimmune diseases at a time when treatment options were limited or nonexistent. That experience shaped his commitment to supporting teams who are working to change what’s possible in biologics and bring new therapies to patients who are still waiting for answers.

We’re grateful for leaders like Tristan, whose work is driven by both expertise and purpose, and whose impact extends far beyond the lab.

Connect with Tristan for any questions around commercial operations!

"

As we enter 2026, the focus across biopharma is shifting from experimentation with AI to measurable impact.

The next phase will be defined by improved data quality, earlier signal detection, and systems that reduce variability across manufacturing networks, not by fully automated plants.

We’re excited to contribute to that shift in the year ahead.

#2026

As the year winds down, we’re reflecting on the progress made across biologics development and manufacturing, and the work still ahead.

The final weeks of the year offer a moment to pause, reset, and prepare for the next phase of ex*****on. We look forward to reconnecting in January and continuing conversations around how AI and better data foundations can ease capacity pressure across the industry.

Wishing our partners and peers a restful holiday season.

Axio BioPharma will be attending JPM Week 2026 in San Francisco.

With the industry navigating capacity constraints, development risk, and increasing complexity, our focus is on applying practical AI to stabilize biologics manufacturing and enable better decision-making earlier in development.

If you’ll be at JPM and are interested in ex*****on-focused approaches to biologics development and scale, we’d love to connect.

As we gather with family, friends, and colleagues, the entire Axio BioPharma team would like to express our deepest gratitude to everyone who plays a part in our journey.

We're especially thankful for:

· Our amazing employees who show up each day with brilliance, passion and teamwork.

· Our partners and clients who trust us as we pioneer AI-driven biomanufacturing and help bring life-changing therapies closer to patients.

· Our supporters, from investors to academic collaborators, who share our vision for faster, smarter biologics development.

· Our community in Madison, Wisconsin and beyond, your belief in our mission fuels our drive.

This year, together we've made meaningful strides, building our platform, expanding capacity, and moving faster than ever toward a future where therapeutics reach patients sooner. We couldn't do it without you.

As we pause to give thanks, we're also energized for what's ahead. From all of us at Axio: we wish you a joyful, restful Thanksgiving filled with warmth, good company and optimism for the next chapter.

🧡